Drug news
Drisapersen filed at FDA for treatment of Duchenne Muscular Dystrophy- Prosena N.V.
Prosensa Holding N.V. (RNA) has announced that it has commenced the submission process for a New Drug Application (NDA) regulatory filing to the FDA for its lead exon-skipping drug candidate, drisapersen, for treating Duchenne Muscular Dystrophy (DMD). The drug received "Fast Track status" from the FDA, making it eligible for a rolling review of an NDA and was also granted "Breakthrough Therapy Designation" in June 2013.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.